BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 220.52

Change

0.00 (0.00)%

Market Cap

USD 32.39B

Volume

2.21M

Avg Analyst Target

USD 323.61 (+46.75%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Biogen Inc (BIIB) Stock Analysis:
Based on the Biogen Inc stock forecasts from 24 analysts, the average analyst target price for Biogen Inc is USD 323.61 over the next 12 months. Biogen Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Biogen Inc is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Biogen Inc’s stock price was USD 220.52. Biogen Inc’s stock price has changed by -18.78% over the past week, -14.89% over the past month and -18.16% over the last year.

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FU ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

N/A

USD184.36B 109.14 24.31
SNY Sanofi

N/A

USD128.86B 18.48 12.23
AMGN Amgen Inc

N/A

USD128.27B 23.47 12.99
GILD Gilead Sciences Inc

N/A

USD85.94B 11.72 8.95
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
HZNP Horizon Therapeutics Public Li..

N/A

USD19.60B 36.71 24.06
GRFS Grifols S.A

N/A

USD11.21B 22.42 12.46
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16
CRXT Clarus Therapeutics Holdings I..

N/A

USD0.03B N/A N/A
CRXTW Clarus Therapeutics Holdings I..

N/A

N/A N/A N/A

ETFs Containing BIIB

Symbol Name Weight Mer Price(Change) Market Cap
UBIO ProShares UltraPro Nasdaq.. 6.30 % 0.95 %

N/A

USD0.02B
BIOT:LSE L&G Pharma Breakthrough U.. 4.43 % 0.75 %

N/A

USD8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.03B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.79 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.59 %

N/A

USD0.02B
BIOT L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

N/A
OSX2:XETRA Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

N/A

N/A
CEM2:XETRA iShares US Equity Buyback.. 0.00 % 0.55 %

N/A

USD4.53M
BBCK:XETRA Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.06B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.44B
CEM2:F iShares US Equity Buyback.. 0.00 % 0.55 %

N/A

USD4.53M
BBCK:F Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.06B
SPMV:PA Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
MVUS:PA Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
BUYB:PA Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.06B
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.57B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.19B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

N/A

USD0.44B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.44B
DQML Reality Shares Fundstrat .. 0.00 % 0.69 %

N/A

USD2.62M
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

USD0.44B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
PKW Invesco BuyBack Achievers.. 0.00 % 0.62 %

N/A

USD1.54B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

N/A

USD0.28B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.50 %

N/A

USD0.20B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

N/A

USD9.98B
FLAG First Light Acquisition G.. 0.00 % 1.44 %

N/A

USD0.28B
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

N/A

USD0.01B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD7.95M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.09% 44% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.09% 44% F 48% F
Trailing 12 Months  
Capital Gain -18.16% 29% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.16% 29% F 41% F
Trailing 5 Years  
Capital Gain -19.47% 29% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.47% 14% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 1.08% 43% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.08% 29% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 18.72% 29% F 76% C
Risk Adjusted Return 5.78% 29% F 28% F
Market Capitalization 32.39B 50% F 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.58 71% C- 39% F
Price/Book Ratio 3.28 71% C- 37% F
Price / Cash Flow Ratio 7.66 88% B+ 39% F
EV/EBITDA 12.95 57% F 51% F
Management Effectiveness  
Return on Equity 19.47% 71% C- 85% B
Return on Invested Capital 18.46% 89% B+ 87% B+
Return on Assets 6.55% 71% C- 85% B
Debt to Equity Ratio 69.40% 71% C- 30% F
Technical Ratios  
Short Ratio 1.41 75% C 66% D
Short Percent 1.89% 38% F 59% F
Beta 0.42 57% F 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.